New drug ALN-AGT01 RVR tested in healthy people for safety
NCT ID NCT06675565
First seen Sep 30, 2025 · Last updated May 16, 2026 · Updated 26 times
Summary
This early-stage study tested the safety and how the body processes a new drug called ALN-AGT01 RVR. It involved 42 healthy adults who received either a single dose of the drug or a placebo. The main goal was to check for side effects and measure drug levels in the blood and urine.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Trial Site
Montreal, Canada
Conditions
Explore the condition pages connected to this study.